The CMS toxin anatoxin-A interacts with α4β2-nicotinic acetylcholine receptors in human cortex

Alzheimer's Reports

Volumn 2, Issue 5, 1999, Pages 263-266

  Durany, Nuria ^a   Riederer, Peter ^a   Deckert, Jürgen ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005230218     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bradford MW (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
2. Carmichael W, Biggs DF and Gorham PR (1978). Toxicology and pharmacological action of anabaena flos-aquae toxin. Science 187, 542-544.
3. Coyle JT, Price DL and DeLong MR (1983). Alzheimer's disease: a disorder of central cholinergic innervation. Science 219, 1184-1190.
4. Fuxe K, Rosen L, Lippoldt A et al. (1994). Chronic continuous infusion of nicotine increases the disappearance of choline acetyltransferase immunoreactivity in the cholinergic cell bodies of the medial septal nucleus following a partial unilateral transection of the fimbria fornix. Clin Invest 72, 262-268.
5. Garcia-Colunga J, Awad JN and Miledi R (1997). Blockage of muscle and neuronal acetylcholine receptors by fluoxetine (prozac). Proc Natl Acad Sci USA 94, 2041-2044.
6. Goldman D, Deneris E, Luyten W et al. (1987). Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system. Cell 489, 965-973.
7. 3H)cytisine binding to human brain membrane preparations. Brain Res 600, 127-133.
8. 3H)epibatidine binding to cholinergic receptors in rat and human brain. J Pharmacol Exp Ther 48, 280-287.
9. McPherson GA (1985). Analysis of radioligand binding experiments. J Pharmacol Methods 14, 213-228.
10. Meldrum BS and Garthwaite J (1990). Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11, 379-387.
11. Qian C, Tongchuan L, Shen TY et al. (1993). Epibatidine is a nicotinic analgesic. Eur J Pharmacol 250, R13-R14.
12. Rosenstein DL, Craig Nelson J and Jacobs SC (1993). Seizures associated with antidepressants: a review. J Clin Psychiatr 54, 289-299.
13. Rupniak NMJ, Patel S, Marwood R et al. (1994). Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br J Pharmacol 113, 1487-1493.
14. Schofield GG, Witkpo B, Warnick JE and Albuquerque EX (1981). Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc Natl Acad USA 78, 5240-5244.
15. 3H)nicotine. J Neurochem 45, 604-610.
16. Spande TF, Garraffo HM, Edwards MW et al. (1992). Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J Am Chem Soc 114, 3475-3478.
17. Stolerman IP, Albuquerque EX and Garcha HS (1992). Behavioral effects of anatoxin, a potent nicotinic agonist in rats. Neuropharmacology 31, 311-314.
18. Thomas P, Stephens M, Wilkie G et al. (1993). (+)Anatoxin-A is a potent agonist at neuronal nicotinic acetylcholine receptors. J Neurochem. 60, 2308-2311.
19. Warpman U and Nordberg A (1995). Epibaditine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. NeuroReport 6, 2419-2423.
20. Weiland s, Witzemann V, Villarroel A et al. (1997). An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett 398, 91-96.
21. Whitehouse PJ, Price DL, Struble RG et al. (1982). Alzheimer's disease and senile dementia: loss of neurones in the basal forebrain. Science 215, 1237-1239.
22. Zhang X, Stjernlöf P, Adem A and Nordberg A (1987). Anatoxin-A: a potent ligand for nicotinic cholinergic receptors in rat brain. Eur J Pharmacol 135, 457-458.